Date	e:2022/5/2	7	
	Name:Jiamir		
Man	uscript Title: Developn	nent and external validati	on of prognostic nomograms for liver disease-free and overal
surv	ival in locally advanced rect	al cancer with neoadjuvar	nt therapy: a post cohort study based on the FOWARC trial
Man	uscript number (if known):		
relate part to trelate	ted to the content of your miles whose interests may be ansparency and does not not interest, it	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. is preferable that you do	relationships/activities/interests listed below that are ins any relation with for-profit or not-for-profit third if the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.  ps/activities/interests as they relate to the current
to th	•	nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript.
	em #1 below, report all sup time frame for disclosure is	·	d in this manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		-	
2	Crants or contrasts from	Time frame: pas	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	X None	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
	testimony		
	,		
7	Support for attending	XNone	
	meetings and/or travel		
_			
8	Patents planned, issued or	XNone	
	pending		
_			
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10		V. None	
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	·		
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X_None	
	financial interests		
<b>5</b> 1.		. (1) (1)	
Plea	ase summarize the above co	ntlict of interest in the follo	owing box:

None		

Date	e:2022/5/2	7	
You	r Name: Tuoya	ng Li	
Mar	nuscript Title: Developr	nent and external validation	on of prognostic nomograms for liver disease-free and overal
			nt therapy: a post cohort study based on the FOWARC trial
Mar	nuscript number (if known):		
related to trelated The	ted to the content of your n ies whose interests may be ransparency and does not no tionship/activity/interest, it	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. is preferable that you do	relationships/activities/interests listed below that are ins any relation with for-profit or not-for-profit third if the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.  os/activities/interests as they relate to the current
to the	ne epidemiology of hypertentication, even if that medica	nsion, you should declare to the state of th	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript.  I in this manuscript without time limit. For all other items,
		Name all anglet a state	Constitution of Community
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	l planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	
	-		

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
	testimony		
	,		
7	Support for attending	XNone	
	meetings and/or travel		
_			
8	Patents planned, issued or	XNone	
	pending		
_			
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10		V. None	
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	·		
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X_None	
	financial interests		
<b>5</b> 1.		. (1) (1)	
Plea	ase summarize the above co	ntlict of interest in the follo	owing box:

None		

Date	e:2022/5/2	7	
You	r Name: Yuanl	v Xiao	
Mar	uscript Title: Developr	nent and external validation	on of prognostic nomograms for liver disease-free and overall
surv	ival in locally advanced rect	al cancer with neoadjuvar	nt therapy: a post cohort study based on the FOWARC trial
Man	uscript number (if known):		
relate to trelate	ted to the content of your n ies whose interests may be ansparency and does not no tionship/activity/interest, it	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. is preferable that you do	relationships/activities/interests listed below that are ins any relation with for-profit or not-for-profit third if the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.  os/activities/interests as they relate to the current
to the	ne epidemiology of hypertentication, even if that medica	nsion, you should declare a tion is not mentioned in the port for the work reported	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript.  I in this manuscript without time limit. For all other items,
tile	time name for disclosure is	the past 30 months.	
		Name all entities with	Specifications/Comments
		whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	Il planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	X None	
	<u> </u>	<del></del>	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
	testimony		
	,		
7	Support for attending	XNone	
	meetings and/or travel		
_			
8	Patents planned, issued or	XNone	
	pending		
_			
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10		V. None	
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	·		
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X_None	
	financial interests		
<b>5</b> 1.		. (1) (1)	
Plea	ase summarize the above co	ntlict of interest in the follo	owing box:

None		

e:2022/5/2	7	
nuscript Title: Developr	nent and external validati	on of prognostic nomograms for liver disease-free and overa
	•	nt therapy: a post cohort study based on the FOWARC trial
nuscript number (if known):		
ited to the content of your name ites whose interests may be ransparency and does not nationship/activity/interest, it following questions apply t	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias. is preferable that you do	f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
nuscript only.		
he epidemiology of hyperted dication, even if that medicatem #1 below, report all sup	nsion, you should declare tion is not mentioned in to port for the work reported	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript.  d in this manuscript without time limit. For all other items,
	Name all autities with	Specifications/Comments
	whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Time frame: Since the initia	l planning of the work
All support for the present	X None	
manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.		
provision of study materials, medical writing, article processing charges, etc.)	Time frame: pas	t 36 months
provision of study materials, medical writing, article processing charges, etc.)	Time frame: pasXNone	t 36 months
provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated		t 36 months
provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).	XNone	t 36 months
provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).	XNone	t 36 months
	r Name: Jinxin nuscript Title: Developmy vival in locally advanced rect nuscript number (if known): the interest of transparency, ated to the content of your maties whose interests may be ransparency and does not notionship/activity/interest, it following questions apply to nuscript only.  author's relationships/activity he epidemiology of hyperteredication, even if that medicatem #1 below, report all supplime frame for disclosure is	In Name: Jinxin Lin

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
	testimony		
	,		
7	Support for attending	XNone	
	meetings and/or travel		
_			
8	Patents planned, issued or	XNone	
	pending		
_			
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10		V. None	
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	·		
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X_None	
	financial interests		
<b>5</b> 1.		. (1) (1)	
Plea	ase summarize the above co	ntlict of interest in the follo	owing box:

None		

Date	e:2022/5/2	7	
	· Name: Xiaoqi		
Man	uscript Title: Developn	nent and external validation	on of prognostic nomograms for liver disease-free and overal
surv	ival in locally advanced rect	al cancer with neoadjuvar	nt therapy: a post cohort study based on the FOWARC trial
Man	uscript number (if known):		
relate to trelate	ted to the content of your miles whose interests may be ansparency and does not not interest, it	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. is preferable that you do	relationships/activities/interests listed below that are ins any relation with for-profit or not-for-profit third if the manuscript. Disclosure represents a commitment of the graph of the second of
to th	•	nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript.
	em #1 below, report all sup time frame for disclosure is	·	d in this manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	l planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	t 26 months
2	Grants or contracts from	X None	- So months
-	any entity (if not indicated in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
	testimony		
	,		
7	Support for attending	XNone	
	meetings and/or travel		
_			
8	Patents planned, issued or	XNone	
	pending		
_			
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10		V. None	
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	·		
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X_None	
	financial interests		
<b>5</b> 1.		. (1) (1)	
Plea	ase summarize the above co	ntlict of interest in the follo	owing box:

None		

Date	e:2022/5/2	7	
You	r Name: Shaoy	ong Peng	
Mar	nuscript Title: Developr	nent and external validation	on of prognostic nomograms for liver disease-free and overa
surv	ival in locally advanced rect	al cancer with neoadjuvar	nt therapy: a post cohort study based on the FOWARC trial
Mar	nuscript number (if known):		
related to trelated The	ted to the content of your n ies whose interests may be ransparency and does not no tionship/activity/interest, it	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. is preferable that you do	relationships/activities/interests listed below that are ns any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.  os/activities/interests as they relate to the current
to the	ne epidemiology of hypertentication, even if that medica	nsion, you should declare a tion is not mentioned in the port for the work reported	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript.  I in this manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	l planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
	testimony		
	,		
7	Support for attending	XNone	
	meetings and/or travel		
_			
8	Patents planned, issued or	XNone	
	pending		
_			
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10		V. None	
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	·		
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X_None	
	financial interests		
<b>5</b> 1.		. (1) (1)	
Plea	ase summarize the above co	ntlict of interest in the follo	owing box:

None		

Date	e:2022/5/2	.7	
You	r Name:Mingz	zhe Huang	
			on of prognostic nomograms for liver disease-free and overal
surv	rival in locally advanced rect	tal cancer with neoadjuvar	nt therapy: a post cohort study based on the FOWARC trial
Mar	nuscript number (if known):		
rela part to to rela The	ted to the content of your n ies whose interests may be ransparency and does not n tionship/activity/interest, it	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. t is preferable that you do	relationships/activities/interests listed below that are ns any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment of the manuscript of the manuscript. Disclosure represents a commitment of the second o
to tl		nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript.
	em #1 below, report all sup time frame for disclosure is	•	I in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initia	l planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	t 36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
•	in item #1 above).	, , , , , , , , , , , , , , , , , , ,	
3	Royalties or licenses	XNone	
4	Communities C	V N-	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
	testimony		
	,		
7	Support for attending	XNone	
	meetings and/or travel		
_			
8	Patents planned, issued or	XNone	
	pending		
_			
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10		V. None	
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	·		
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X_None	
	financial interests		
<b>5</b> 1.		. (1) (1)	
Plea	ase summarize the above co	ntlict of interest in the follo	owing box:

None		

Date	e:2022/5/2	7	
	r Name:Xuebi		
surv	• •	al cancer with neoadjuvar	on of prognostic nomograms for liver disease-free and overal nt therapy: a post cohort study based on the FOWARC trial
rela part to to to rela  The mar  The to	ted to the content of your naties whose interests may be ransparency and does not not itionship/activity/interest, it following questions apply the suscript only.  author's relationships/activity of hyperterestication, even if that medical	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. is preferable that you do the author's relationship rities/interests should be go nsion, you should declare tion is not mentioned in the	os/activities/interests as they relate to the <u>current</u> defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: pas	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
	testimony		
	,		
7	Support for attending	XNone	
	meetings and/or travel		
_			
8	Patents planned, issued or	XNone	
	pending		
_			
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10		V. None	
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	·		
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X_None	
	financial interests		
<b>5</b> 1.		. (1) (1)	
Plea	ase summarize the above co	ntlict of interest in the follo	owing box:

None		

Date	e:2022/5/2	7	
You	r Name:Linbir	n Cai	
surv		tal cancer with neoadjuva	on of prognostic nomograms for liver disease-free and overall nt therapy: a post cohort study based on the FOWARC trial
relar part to to to relar. The man to	ted to the content of your naties whose interests may be ransparency and does not not it in the property of the content of the property of the content of th	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. It is preferable that you do to the author's relationship wities/interests should be go nsion, you should declare ation is not mentioned in the	os/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: pas	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	X None	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
	testimony		
	,		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
_			
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10		V. None	
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	·		
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
<b>5</b> '		. (1) (1)	
Plea	ase summarize the above co	nflict of interest in the foll	owing box:

None			

e:2022/5/2	7		
Name:Pinzh	u Huang		
		on of prognostic nomograms for liver disease-free and over	all
ival in locally advanced rect	al cancer with neoadjuvan	it therapy: a post cohort study based on the FOWARC trial_	
uscript number (if known):			
ted to the content of your maies whose interests may be an sparency and does not not ionship/activity/interest, it following questions apply to uscript only.  author's relationships/activity e epidemiology of hyperterication, even if that medical em #1 below, report all supplements.	nanuscript. "Related" mean affected by the content of ecessarily indicate a bias. is preferable that you do to the author's relationship wities/interests should be dension, you should declare a tion is not mentioned in the	ns any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment of you are in doubt about whether to list a so.  It is a so, a so a so a so a so a so a so a	
	Name all entities with	Specifications/Comments	
	whom you have this	(e.g., if payments were made to you or to your	
	· ·	institution)	
	-		
	I	planning of the work	
	XNone		
- T			
<u> </u>			
	Time frame: nast	36 months	
Grants or contracts from	·		
· · · · · · · · · · · · · · · · · · ·	X None		
,			
Consulting fees	XNone		
	Name:Pinzh juscript Title: Developmival in locally advanced rectauscript number (if known): the interest of transparency, ted to the content of your miles whose interests may be ansparency and does not not it in the interest of transparency, and does not not it in the interest of transparency, and does not not it in the interest of transparency and does not not it in the interest of transparency and does not not it in the interest of transparency and does not not it in the interest of transparency and does not not it in the interest of transparency and does not not it in the interest of transparency and does not not it in the interest of the interes	Pinzhu Huang  Juscript Title: Development and external validation in locally advanced rectal cancer with neoadjuvariance in locally advanced in locally advanced rectal cancer with neoadjuvariance in locally advanced in local part of the content of ansparency and does not necessarily indicate a bias. Licionship/activity/interest, it is preferable that you do following questions apply to the author's relationship uscript only.  The frame is should be go in local part of the local par	Name:Pinzhu Huang

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
	testimony		
	,		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
_			
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10		V. None	
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	·		
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
<b>5</b> '		. (1) (1)	
Plea	ase summarize the above co	nflict of interest in the foll	owing box:

None			

Date:	2022/5/27	
Your Name:	Meijin Huan	g
Manuscript Title: survival in locally	•	d external validation of prognostic nomograms for liver disease-free and overall er with neoadjuvant therapy: a post cohort study based on the FOWARC trial
Manuscript numb	er (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

	_	T			
5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
7	Support for attending	XNone			
	meetings and/or travel				
8	Patents planned, issued or	X None			
	pending				
	F				
9	Participation on a Data	X None			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	X None			
	in other board, society,				
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	X None			
12	Receipt of equipment,	X None			
	materials, drugs, medical				
	writing, gifts or other				
	services				
13	Other financial or non-	XNone			
	financial interests	_			
			,		
Plea	Please summarize the above conflict of interest in the following box:				

None		